French Guiana Wellness Network: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on French Guiana Wellness Network.

Press releases published on September 23, 2026

Sep. 23, 2026

BioAro Launches AI-Assisted LONgevity+™ Bioactives in the U.S. and U.K.

Indeterminate GlobeNewswire

Sep. 23, 2026

PhAST Corp. Receives FDA Clearance for Rapid Antimicrobial Susceptibility Testing Directly From Positive Blood Cultures

Indeterminate GlobeNewswire

Sep. 23, 2026

Altimmune to Participate in Stifel Cardiometabolic Forum

Indeterminate GlobeNewswire

Sep. 23, 2026

Adaptyx Biosciences Granted FDA Breakthrough Device Designation For Its Continuous Cortisol Monitoring Technology and Is Accepted into FDA’s Total Product Life Cycle Advisory Program

Indeterminate GlobeNewswire

Sep. 23, 2026

Clearmind Enhances U.S. IP Presence with Publication of Three Patent Applications Covering LSD, Ketamine and Ibogaine Combinations

Indeterminate GlobeNewswire

Sep. 23, 2026

Acoramidis Demonstrates Real-World Benefit Versus Tafamidis in ATTR-CM, Reducing Risk of Clinical Worsening

Indeterminate GlobeNewswire

Sep. 23, 2026

Artelo Biosciences Files New Provisional Patent Application Covering ART27.13 for Obesity, Alone and in Combination with GLP-1 Receptor Agonists, Following Unexpected Nonclinical Findings

Indeterminate GlobeNewswire

Sep. 23, 2026

Entente Education Canada urges federal government to take steps to improve cash flow and tax fairness for seniors, caregiver support

Indeterminate GlobeNewswire

Sep. 23, 2026

Wave Life Sciences Initiates Phase 2a Combination Trial of WVE-007 (GalNAc-siRNA) with Tirzepatide for Obesity

Indeterminate GlobeNewswire

Sep. 23, 2026

Artiva Biotherapeutics Announces Oral Presentation of AlloNK® Clinical Data at the 17th International Symposium on Sjögren’s Disease

Indeterminate GlobeNewswire

Sep. 23, 2026

Biomea Fusion Announces Termination of Proposed Public Offering of Securities

Indeterminate GlobeNewswire

Sep. 23, 2026

AC Immune Reports Positive Safety & Immunogenicity at week-100 in Part 1 of VacSYn Phase 2 Trial of ACI-7104

Indeterminate GlobeNewswire

Sep. 23, 2026

Avalo Therapeutics to Present at the European Academy of Dermatology and Venereology (EADV) 2026 Congress

Indeterminate GlobeNewswire

Sep. 23, 2026

Lexeo Therapeutics to Participate in the Stifel 2026 Virtual Cardiometabolic Forum

Indeterminate GlobeNewswire

Sep. 23, 2026

Oruka Therapeutics Announces Positive Week 28 Data for ORKA-001 from the Ongoing EVERLAST-A Trial Showing Deepening of Responses Without Additional Dosing

Indeterminate GlobeNewswire

Sep. 23, 2026

Verano to Report Third Quarter 2026 Financial Results on October 29, 2026

Indeterminate GlobeNewswire

Sep. 23, 2026

Psyence BioMed Announces Strategic Ibogaine Investment

Indeterminate GlobeNewswire

Sep. 23, 2026

Immunovant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus Erythematosus

Indeterminate GlobeNewswire

Sep. 23, 2026

Grey Matters Announces the Closing of its Equity and Convertible Debenture Private Placement totalling CAD $1.12 Million

Indeterminate GlobeNewswire

Sep. 23, 2026

Seer and Nanyang Technological University to Present Early Findings from Landmark PRECISE-SG100K Proteomics Study at HUPO 2026

Indeterminate GlobeNewswire